- Joined
- 28 August 2022
- Posts
- 7,232
- Reactions
- 11,798
Or is it slightly out of its weight division?????
Or is it slightly out of its weight division?????25.6% up for the month so far.
Well done Iggy.
Punching near 52 week highs also.
View attachment 158485
whoops.My pick again for the stock tipping comp.
. Waiting on approval from Food and Drug admin, and if approved should turn things around.
Ouch. That would have hurt the investors.whoops.
Mesoblast has told investors it will have to conduct an adult trial before receiving approval from the US regulator to market its most advanced product.
The shares slumped 50 per cent to 54.5¢.
The company will meet with the FDA in 45 days to discuss the adult trial for stem-cell-based injectable treatment for acute-graft versus host disease approved for use
that depends on if Iggy is buying ( i would be if NIC dropped 40 to 50% on speculation and rumor )whoops.
Mesoblast has told investors it will have to conduct an adult trial before receiving approval from the US regulator to market its most advanced product.
The shares slumped 50 per cent to 54.5¢.
The company will meet with the FDA in 45 days to discuss the adult trial for stem-cell-based injectable treatment for acute-graft versus host disease approved for use
PLACEMENT AND ACCELERATED NON-RENOUNCEABLE ENTITLEMENT OFFER TO RAISE UP TO A$97.0M
Melbourne, Australia; December 4, 2023:
Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced a placement and entitlement offer to raise up to A$97.0 million. Key Highlights The Placement and Entitlement Offer has been structured as:
• an institutional placement of up to approximately 120 million new fully paid ordinary shares in Mesoblast at an offer price of A$0.30 per new share (Offer Price) to raise up to A$36.0 million (Placement); and
• a 1 for 4 pro-rata accelerated non-renounceable entitlement offer of new fully paid ordinary shares in Mesoblast to existing eligible shareholders (Entitlement Offer), at the Offer Price per new share to raise up to approximately A$61 million, comprising an accelerated institutional entitlement offer (Institutional Entitlement Offer) and a retail entitlement offer (Retail Entitlement Offer).
• In addition to being able to apply for New Shares under the Retail Entitlement Offer, Eligible retail shareholders who have taken up all of their Entitlement will also have the ability to apply for additional New Shares under a 'top-up' facility (Top-Up Facility).
Approximately 323 million shares will be issued under the Placement and Entitlement Offer (New Shares) which represents approximately 39.7% of current shares on issue.
The Offer Price of A$0.30 per New Share represents a discount of:
• 20.0% to the theoretical ex-rights price (TERP)1 of A$0.375; and
• 25.9% to Mesoblast’s last close price of A$0.405 on 30 November 2023. The New Shares will rank equally with existing fully paid ordinary shares on issue in Mesoblast.
Bell Potter Securities Limited will act as the sole lead manager and sole bookrunner of the Placement and Entitlement Offer (Lead Manager).
Use of Proceeds
Proceeds from the Placement and Entitlement Offer and existing cash reserves will be used to fund the adult Phase 3 registration trials for steroid-refractory acute-graft versus host disease and for chronic lower back pain, and general corporate purposes.
Who is actually surprised?
OK news for me
Big BFG rise today which is pleasing. Maybe this is part of it.OK news for me
i hold BFG they will score a few bucks out of this
but crikey Peter Hall sure knew when to pull up stakes ( i held HHL and HHV at the time )
Another one for me that turned from and orange to a very bitter lemon some time ago.MSB thread has been really quiet the last few months.
Even though there has been a lot happening with it. Not much of it good I am afraid.
Not sure if I'll participate in the latest SPP. But I hope that as the bottom had been reached it may have a good 12mths.
I'll keep a regular tab on this stock through out the year and prompt discussion here.
@UMike Was a stock that i was consistently trading and then got caught with my dacks down around my ankles. Overall didn't end up to deep in the minus department. What caught me out bought a very sizeable chunk and then the hole in the bucket appeared glug glug glug.If it is of any consolement this was a disaster for me in my personal around 8 years ago.
Traded and then bought a substantial amount in the super and put it in the bottom draw for a 400+% gain.
So can lightning strike twice?
Don't expect it to ever get near $4+ again.
But anything over $1..... esp If I participate in the SSP would get me outta trouble and back to the initial gain.
Hum, just a new record to break in the next month for them..I learnt my lesson, any SP rise is followed within days by a SPP..and rince again...More like a 15 year low.
Doubt they ever traded lower.
UNITED STATES FOOD & DRUG ADMINISTRATION (FDA) GRANTS MESOBLAST RARE PEDIATRIC DISEASE DESIGNATION FOR REVASCOR® (REXLEMESTROCEL-L) IN CHILDREN WITH CONGENITAL HEART DISEASE
Capital raising comingHealth Care company Mesoblast (ASX:MSB) gained more than 9 per cent after receiving orphan-drug designation (ODD) and rare pediatric disease designation (RPDD) from the US Food and Drug Administration (FDA) for its cell therapy, Revascor.
The designations stem from positive results in a trial including children with a life-threatening congenital heart condition.
MSB closed at 30 cents.
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?